In conclusion, the results presented here suggest that bexmarilimab can target CLEVER-1 on malignant myeloid cells to potentially increase antigen-presentation capability and promote sensitivity to cytotoxic agents, supporting the ongoing clinical development of bexmarilimab in combination with SoC in myeloid malignancies (NCT05428969). The gene discussed is STAB1; the disease is myeloid neoplasm.